Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma

Exclusion Criteria

• •1. history or evidence of severe cardiac disease (e.g., NYHA functional class III or IV)
• •2. clinical or medical history of unstable angina, acute coronary syndrome, myocardial infarction or revascularization with 6 months
• •3. ventricular tachyarrhythmias requiring ongoing treatment
• •4. History or evidence clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation
• •5. Clinically significant impaired renal or hepatic function
• •6. Stroke within 12 month before trial entry.
• •7. Known serious allergies to the fluorescein dye use in angiography
• •8. Known contraindications to the components of Lucentis® formulation.
• •Ocular concomitant conditions/ diseases
• •1. Active intraocular inflammation (grade trace or above) in either eye
• •2. Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye
• •3. History of uveitis in either eye
• •4. Treatment with anti-angiogenic drugs (pegaptanib sodium, anecortave acetate,bevacizumab, ranibizumab, etc.) or intravitreal corticosteroids in either eye within 4 months prior to inclusion
• •5. Angle block glaucoma
• •6. Phthisis
• •7. Intraocular Pressure \<10mmHg
• •Compliance/ Administrative
• •1. Previous participation in any clinical studies of investigational drugs (excluding vitamins and minerals) within 1 month (or a period corresponding to 5 half-lives of the investigational drug, whatever is longer) prior to inclusion
• •2. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent.
• •3. Pregnant or nursing (lactating) women
• •4. Inability to comply with study or follow-up procedures.
• •5. Any treatment with an investigational agent in the past 60 days for any condition.